TY - JOUR
T1 - Routine CSF parameters as predictors of disease course in multiple sclerosis
T2 - an MSBase cohort study
AU - Dekeyser, Cathérine
AU - Hautekeete, Matthias
AU - Cambron, Melissa
AU - Van Pesch, Vincent
AU - Patti, Francesco
AU - Kuhle, Jens
AU - Khoury, Samia
AU - Scott, Jeanette Lechner
AU - Gerlach, Oliver
AU - Lugaresi, Alessandra
AU - Maimone, Davide
AU - Surcinelli, Andrea
AU - Grammond, Pierre
AU - Kalincik, Tomas
AU - Habek, Mario
AU - Willekens, Barbara
AU - Macdonell, Richard
AU - Lalive, Patrice
AU - Csepany, Tunde
AU - Butzkueven, Helmut
AU - Boz, Cavit
AU - Tomassini, Valentina
AU - Foschi, Matteo
AU - Sánchez-Menoyo, José Luis
AU - Altintas, Ayse
AU - Mrabet, Saloua
AU - Iuliano, Gerardo
AU - Sa, Maria Jose
AU - Alroughani, Raed
AU - Karabudak, Rana
AU - Aguera-Morales, Eduardo
AU - Gray, Orla
AU - de Gans, Koen
AU - van der Walt, Anneke
AU - McCombe, Pamela A.
AU - Deri, Norma
AU - Garber, Justin
AU - Al-Asmi, Abdullah
AU - Skibina, Olga
AU - Duquette, Pierre
AU - Cartechini, Elisabetta
AU - Spitaleri, Daniele
AU - Gouider, Riadh
AU - Soysal, Aysun
AU - Van Hijfte, Liesbeth
AU - Slee, Mark
AU - Amato, Maria Pia
AU - Buzzard, Katherine
AU - Laureys, Guy
N1 - Publisher Copyright:
© 2024 BMJ Publishing Group. All rights reserved.
PY - 2024/4/3
Y1 - 2024/4/3
N2 - Background It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course. Methods This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis. Results In total, 11 245 participants were included of which 93.7% (n=10 533) were persons with relapsing-remitting MS (RRMS). In RRMS, the presence of CSF oligoclonal bands (OCBs) was associated with shorter time to disability milestones EDSS 4 (adjusted HR=1.272 (95% CI, 1.089 to 1.485), p=0.002), EDSS 6 (HR=1.314 (95% CI, 1.062 to 1.626), p=0.012) and EDSS 7 (HR=1.686 (95% CI, 1.111 to 2.558), p=0.014). On the other hand, the presence of CSF pleocytosis (≥5 cells/ µL) increased time to moderate disability (EDSS 4) in RRMS (HR=0.774 (95% CI, 0.632 to 0.948), p=0.013). None of the CSF variables were associated with time to disability milestones in persons with primary progressive MS (PPMS). The presence of CSF pleocytosis increased ARR2 in RRMS (adjusted R2=0.036, p=0.015). Conclusions In RRMS, the presence of CSF OCBs predicts shorter time to disability milestones, whereas CSF pleocytosis could be protective. This could however not be found in PPMS. CSF pleocytosis is associated with short-term inflammatory disease activity in RRMS. CSF analysis provides prognostic information which could aid in clinical and therapeutic decision-making.
AB - Background It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course. Methods This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis. Results In total, 11 245 participants were included of which 93.7% (n=10 533) were persons with relapsing-remitting MS (RRMS). In RRMS, the presence of CSF oligoclonal bands (OCBs) was associated with shorter time to disability milestones EDSS 4 (adjusted HR=1.272 (95% CI, 1.089 to 1.485), p=0.002), EDSS 6 (HR=1.314 (95% CI, 1.062 to 1.626), p=0.012) and EDSS 7 (HR=1.686 (95% CI, 1.111 to 2.558), p=0.014). On the other hand, the presence of CSF pleocytosis (≥5 cells/ µL) increased time to moderate disability (EDSS 4) in RRMS (HR=0.774 (95% CI, 0.632 to 0.948), p=0.013). None of the CSF variables were associated with time to disability milestones in persons with primary progressive MS (PPMS). The presence of CSF pleocytosis increased ARR2 in RRMS (adjusted R2=0.036, p=0.015). Conclusions In RRMS, the presence of CSF OCBs predicts shorter time to disability milestones, whereas CSF pleocytosis could be protective. This could however not be found in PPMS. CSF pleocytosis is associated with short-term inflammatory disease activity in RRMS. CSF analysis provides prognostic information which could aid in clinical and therapeutic decision-making.
UR - http://www.scopus.com/inward/record.url?scp=85190160325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190160325&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/c927b067-ab3c-3132-bf11-a0627d5e0e9c/
U2 - 10.1136/jnnp-2023-333307
DO - 10.1136/jnnp-2023-333307
M3 - Article
C2 - 38569872
AN - SCOPUS:85190160325
SN - 0022-3050
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
M1 - 23333307
ER -